Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $91,350.00. Following the completion of the sale, the director directly owned 683,083 shares of the company’s stock, valued at $4,159,975.47. The trade was a 2.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Trading Up 0.5%

XERS traded up $0.03 during mid-day trading on Friday, hitting $6.18. The stock had a trading volume of 1,028,207 shares, compared to its average volume of 1,829,779. The stock’s fifty day simple moving average is $6.08 and its 200-day simple moving average is $6.60. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of 103.00 and a beta of 0.78. Xeris Biopharma Holdings, Inc. has a 1-year low of $4.30 and a 1-year high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. As a group, research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

XERS has been the topic of a number of research analyst reports. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of XERS. UBS Group AG boosted its position in Xeris Biopharma by 682.4% during the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after acquiring an additional 1,554,869 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Xeris Biopharma by 67.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, Granahan Investment Management LLC boosted its holdings in Xeris Biopharma by 249.4% during the fourth quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after purchasing an additional 873,236 shares during the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.